# Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

> **NCT03589313** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 6 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** GLPG3067 single dose

## Key facts

- **NCT ID:** NCT03589313
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2018-03-26
- **Final completion:** 2018-03-26
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589313, "Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03589313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*